Phibro Animal Health (PAHC) Projected to Release Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) will likely be issuing its Q1 2027 results after the market closes on Wednesday, November 4th. Analysts expect Phibro Animal Health to announce earnings of $0.7830 per share and revenue of $382.42 million for the quarter. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Investors are encouraged to explore the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, August 26th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14. The business had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. On average, analysts expect Phibro Animal Health to post $3.49 EPS for the current fiscal year and $3.81 EPS for the next fiscal year.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $38.88 on Monday. The business has a fifty day moving average price of $36.99 and a two-hundred day moving average price of $41.12. The stock has a market capitalization of $1.58 billion, a PE ratio of 15.93 and a beta of 0.42. The company has a debt-to-equity ratio of 1.84, a current ratio of 2.96 and a quick ratio of 1.27. Phibro Animal Health has a fifty-two week low of $28.25 and a fifty-two week high of $60.08.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 18th. Weiss Ratings reissued a “hold (c+)” rating on shares of Phibro Animal Health in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.67.

About Phibro Animal Health

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.